FirsthandHealth
medRxiv PreprintsInternational20 November 2026

LCatlas: A Point-Of-Care Tool for Predicting Immunotherapy Outcomes in Non-Small Cell Lung Cancer

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with a minority of patients experiencing durable responses to first-line immune checkpoint inhibitors (ICIs). Currently, there are no easily accessible tools to predict clinical benefit to first-line immunotherapy. To address this gap, we developed LCatlas (https://www.lcatlas.org), a point-of-care web application designed to predict immunotherapy outcomes and inform evidence-based treatment decisions. Using data from 79 NSCLC patients receiving first-line immunotherapy, we extracted demographic, clinical, and mole
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.